CJC-1295 + DAC

CJC-1295 with DAC acts as an agonist of the GHRH receptor (GHRHR) in the anterior pituitary gland. By binding to this receptor, it activates the cAMP signaling pathway, stimulating the synthesis and pulsatile release of growth hormone (GH). The DAC (Drug Affinity Complex) covalently binds to serum albumin, prolonging the peptide's half-life and reducing renal clearance. This allows sustained stimulation of GH secretion without the need for frequent administration.

• GHRH receptor binding: Mimics the action of endogenous GHRH.
• cAMP pathway activation: Increases GH transcription and release.
• Albumin binding: DAC enables prolonged and stable peptide release.
• IGF-1 increase: Released GH stimulates hepatic IGF-1 production.

• Growth hormone deficiency: Investigated as a treatment for GH deficiency in adults and children.
• Anti-aging medicine: Used in unregulated clinics to improve body composition and vitality.
• Athletic performance: Used by athletes to increase muscle mass, reduce fat, and speed recovery.
• Scientific research: Studied to understand the regulation of the GH/IGF-1 axis.

Reported effects include increased lean muscle mass, reduced body fat, improved bone density, enhanced energy and overall well-being, and better sleep quality. Improved post-exercise recovery and collagen synthesis have also been observed, which may benefit skin and joint health. However, these effects have not been rigorously validated in large-scale clinical trials.

The use of CJC-1295 with DAC is not approved by the FDA or EMA, and its long-term safety profile is unknown. Reported adverse effects include injection site pain, redness, swelling, headaches, nausea, fatigue, and in some cases, prolactin elevation or suppression of the endogenous GH/IGF-1 axis. There is a risk of developing acromegaly if used in high doses or for prolonged periods. It is contraindicated in individuals with active cancer, diabetic retinopathy, intracranial hypertension, or hypersensitivity to the compound. It should not be used during pregnancy or breastfeeding. Strict medical monitoring is recommended if used in research.

CJC-1295 with DAC has not been approved by the FDA (United States), EMA (Europe), or any other major regulatory agency for human use. Its status is exclusively for research. In some countries, it may be available in aesthetic or anti-aging clinics under loose local regulations, but it does not have marketing authorization as a drug.

There is no approved standard dosage. In research studies, doses of 1-2 mg administered subcutaneously every 5-8 days have been used. Some protocols suggest doses of 100-200 mcg per kg of body weight per week, divided into 1-2 injections. Dosage should be determined by a qualified healthcare professional in a research setting.

The lyophilized peptide should be stored in a freezer at -20 °C, protected from light and moisture. Once reconstituted with bacteriostatic water or sterile saline, it should be refrigerated at 2-8 °C and used within 7-10 days. Do not freeze after reconstitution. Avoid vigorous shaking to prevent peptide denaturation.